EDMONTON, Jan. 25, 2012 /CNW/ - Medwell Capital Corp. ("Medwell") (TSXV: MWC) announced today that pursuant to its stock option plan the Company has
granted options to directors, officers, employees and consultants
entitling them to purchase up to 3,305,000 common shares at a price of
$0.13 per share on or before January 3, 2021.
For further information please visit www.medwellcapital.com.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within
the meaning of securities laws. Implicit in this information,
particularly in respect of the future outlook of Medwell, and
anticipated events or results, are assumptions based on beliefs of
Medwell's senior management as well as information currently available
to it. While these assumptions were considered reasonable by Medwell at
the time of preparation, they may prove to be incorrect. Readers are
cautioned that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Medwell to take advantage of business
opportunities in the biomedical industry, the granting of necessary
approvals by regulatory authorities as well as general economic, market
and business conditions, and could differ materially from what is
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE Medwell Capital Corp.
For further information:
For further information about Medwell please contact: